Results 201 to 210 of about 692,269 (276)

Computational screening of natural product inhibitor stargeting the MDM2-p53 interaction: docking and molecular dynamics insights for retinoblastoma therapy. [PDF]

Am J Transl Res
Geng Y, Liu X, Kumar S, Geng Y.
europepmc   +1 more source

Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study

MedComm, Volume 7, Issue 10, October 2026.
Envonalkib provides robust and durable benefit in treatment‐naïve ALK‐positive NSCLC, with median PFS of 30.4 months versus 12.0 months for crizotinib. Exploratory biomarker analyses showed that concurrent driver alterations and p53 pathway dysfunction reduce treatment efficacy.
Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpeng Yang   +25 more
wiley   +1 more source

p53 Pathway-Targeted Therapeutic Strategies in Glioblastoma: A CNS-Specific Framework Integrating Therapeutic Resistance, Molecular Stratification, CNS Pharmacology, and Clinical Translation. [PDF]

Drug Des Devel Ther
Bu F, Zeng S, Ma C, Zhang M.
europepmc   +1 more source

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. [PDF]

Cancers (Basel), 2018
Wu CE, Koay TS, Esfandiari A, Ho YH, Lovat P, Lunec J.   +5 more
europepmc   +1 more source

TP53 Mutation Heterogeneity Refines Prognostic Stratification in IDH‐Wildtype Glioma

MedComm, Volume 7, Issue 10, October 2026.
This study reveals that TP53 mutations in IDH‐wildtype gliomas are prognostically heterogeneous. A variant allele frequency (VAF) ≥10% identifies a high‑risk subgroup, and mutations located in the β‑strand region of the DNA‑binding domain confer the poorest outcomes.
Kuilin Liao, Zhi Ye, Songtao Qi, Chang Xu, Yudi Huang, Zhiyong Li, Guozhong Yi, Yuou Qin, Qiuming Pan, Guiling Liu, Chao Chen, Zhuoyang Chen, Hongrui Li, Junxi Wang, Xi'an Zhang, Guanglong Huang, Shanqiang Qu   +16 more
wiley   +1 more source

Recent Exploration of Right-Handed D-Sulfonyl-γ-AApeptides as Potential Tools Toward α-Helical Mimicry. [PDF]

Chempluschem
Fontaine J, Cai J.
europepmc   +1 more source

Advanced Glycation End Products: From Pathogenesis to Treatment

MedComm, Volume 7, Issue 10, October 2026.
Therapeutic landscape of AGE‐targeted intervention. Schematic representation of intervention strategies targeting distinct stages of AGE biology. Upstream prevention aims to reduce exposure and formation through low‐AGE cooking, smoking cessation, glycemic control, and metabolic optimization.
Tak‐Ho Lo, Junying Zou, Jingyi Zhang, Kaijun Lin, Minhui Zhu, Shuangqi Lu, Xin Liu, Mengyao Wu   +7 more
wiley   +1 more source

Balancing Ubiquitination and Deubiquitination in Apoptotic Protein Stability and Cancer Cell Survival. [PDF]

Int J Mol Sci
Choi M, Baek KH.
europepmc   +1 more source

SPG4 Hereditary Spastic Paraplegia: From Etiology to Therapy

Movement Disorders, Volume 41, Issue 10, Page 2592-2605, October 2026.
Abstract Hereditary spastic paraplegias (HSPs) comprise a heterogeneous group of heritable neurodegenerative disorders resulting from mutations in a wide variety of genes. HSP locomotor symptoms include lower limb weakness and spasticity that arise from progressive degeneration of corticospinal axons projecting from the motor cortex to the distal ...
Emanuela Piermarini, Peter W. Baas
wiley   +1 more source

Transcriptomic Stratification Reveals an FRS2-Associated, Proliferation-Independent Phenotype in MDM2-High Sarcomas. [PDF]

Curr Oncol
Sakai T, Aiba H, Yamaguchi M, Hagiwara K, Murakami H, Kimura H.   +5 more
europepmc   +1 more source